Biosimilar Benefit

The WHO has approved a biosimilar version of Herceptin—a “cheap copy” of the gamechanging breast cancer drug. 
 
Herceptin targets HER2+ breast cancer and is considered an “essential medicine,” but its price tag—$20k per patient—is prohibitive. 
 
A disproportionate number of women in low-income countries die of HER2+ because of late diagnoses and no access to affordable treatment. The biosimilar version will be available at a 65% lower cost, bringing the lifesaving medication within reach. 
 
“Effective, affordable breast cancer treatment should be a right for all women, not the privilege of a few,” says WHO Director-General Tedros Adhanom Ghebreyesus.
 
The Guardian

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top